All In Biotech

Drug Trial Radar · NCT06106945

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

226

Planned (sponsor's estimate)

Start

Dec 5, 2023

Primary completion

Jan 24, 2028

Study completion Jan 24, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

Conditions

  • Multiple Myeloma

Interventions

  • AZD0305Drug

    AZD0305 Investigational product

  • ElranatamabDrug

    Module 2 Investigational product

  • PomalidomideDrug

    Module 3 Standard of Care (background treatment)

  • DexamethasoneDrug

    Module 3 Standard of Care (background treatment)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)Time frame: From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3)
  2. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From time of Informed consent to 30 days post end of treatment
  3. Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3)Time frame: From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days)

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Irvine, California · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Ann Arbor, Michigan · Recruiting

  • Research Site

    St Louis, Missouri · Withdrawn

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Fitzroy, Australia · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    Wollongong, Australia · Not yet recruiting

  • Research Site

    Salvador, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Recruiting

  • Research Site

    São Paulo, Brazil · Recruiting

  • Research Site

    Nova Scotia, Canada · Not yet recruiting

  • Research Site

    Hamilton, Ontario, Canada · Recruiting

  • Research Site

    Ottawa, Ontario, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Not yet recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Changsha, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Shenyang, China · Recruiting

  • Research Site

    Lille, France · Recruiting

  • Research Site

    Nantes, France · Recruiting

  • Research Site

    Essen, Germany · Recruiting

  • Research Site

    Freiburg im Breisgau, Germany · Withdrawn

  • Research Site

    Hamburg, Germany · Recruiting

  • Research Site

    Heidelberg, Germany · Not yet recruiting

  • Research Site

    Lübeck, Germany · Recruiting

  • Research Site

    Nuremberg, Germany · Recruiting

  • Research Site

    Tübingen, Germany · Not yet recruiting

  • Research Site

    Würzburg, Germany · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Nagoya, Japan · Recruiting

  • Research Site

    Yamagata, Japan · Recruiting

  • Research Site

    Badalona, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.